2 recruiting, 1 not yet recruiting. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Chen Xiaoping: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. HAIC + Tirelizumab +lenvatinib +liver resection, liver resection - HCC | Phase 4 | Not yet recruiting | Chen Xiaoping | 312 | 2024-05-01 | 2024-03-15 |
| Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma PD-1 monoclonal antibody and lenvatinib, PD-1 monoclonal antibody - HCC | Phase 4 | Recruiting | Chen Xiaoping | 300 | 2024-04-01 | 2024-05-07 |
| Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. HAIC plus PD-1 inhibitors plus lenvatinib, PD-1 inhibitors plus lenvatinib - HCC | Phase 4 | Recruiting | Chen Xiaoping | 300 | 2024-04-01 | 2024-05-07 |
Carcinoma, Hepatocellular (1) · Recurrence (1)
lenvatinib (2) · Hepatectomy (1) · Immune Checkpoint Inhibitors (1) · spartalizumab (1)
China (2)
Xiaoping Chen (2)